| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Classified under Biotechnology (Health Care sector), NVAX's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 264.1K | - | - | |
| VP | 157.1K | - | - | |
| CFO | 136.5K | - | - | |
| VP | 101.4K | - | - | |
| Dir | 73.2K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | Young James F82 | Director | Sell | 10,000 | $8.22 | $82,208.00 | -16.2% | -20.3% | -16.4% | |
| Dec 13, 2024 | King Rachel K. | Director | Sell | 4,150 | $9.02 | $37,435.08 | -21.9% | -10.3% | -27.9% | |
| Jun 21, 2024 | Young James F82 | Director | Sell | 7,500 | $14.09 | $105,675.00 | -10.8% | -10.6% | -54.2% | |
| Jun 18, 2024 | Young James F82 | Director | Sell | 7,500 | $13.72 | $102,880.62 | -9.8% | -4.2% | -54.3% | |
| Jun 17, 2024 | Dubovsky Filip | President, R&D | Sale+OE | 13,904 | $14.47 | $201,164.16 | -17.3% | -6.0% | -53.8% | |
| May 14, 2024 | Dubovsky Filip | President, R&D | Sale+OE | 47,312 | $13.90 | $657,636.80 | -54.8% | -12.1% | -55.8% | |
| Mar 10, 2023 | Glenn Gregory M88 | President, R&D | Buy | 6,000 | $7.17 | $43,041.50 | +70.8% | +17.9% | -16.4% | |
| Mar 31, 2022 | Young James F82 | Director | Sell | 12,500 | $73.58 | $919,764.60 | -16.6% | -29.6% | -90.6% | |
| Jan 3, 2022 | Herrmann John A III91 | EVP, Chief Legal Officer | Sale+OE | 5,000 | $140.91 | $704,533.53 | -56.5% | -47.3% | -93.1% | |
| Dec 31, 2021 | Young James F82 | Director | Sale+OE | 3,750 | $144.16 | $540,600.75 | -4.8% | -48.5% | -92.8% |